David C. Lye
Expertise in
10
conditions

David C. Lye

12 Science Drive 2, 
Singapore, SG 
Expertise in
10
conditions
12 Science Drive 2, 
Singapore, SG 

Overview

David Lye practices practicing medicine in Singapore, Singapore.

Mr. Lye is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Dengue Fever, Viral Hemorrhagic Fever, Methicillin-Resistant Staphylococcus Aureus (MRSA), COVID-19, and Hepato-Pancreato-Biliary Surgery.

He is actively involved in clinical research, co-authoring 369 peer reviewed articles and participating in 3 clinical trials.

Gender

Male

Locations

12 Science Drive 2, Singapore, 117549, Singapore

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Heterologous Prime-boost-boost Vaccine Combinations for Long-term Humoral and Cellular Immunity Against COVID-19
Heterologous Prime-boost-boost Vaccine Combinations for Long-term Humoral and Cellular Immunity Against COVID-19
Enrollment Status: Completed
Publish Date: October 15, 2024
Intervention Type: Biological
Study Phase: Phase 4
CAMERA 2 - Combination Antibiotic Therapy for Methicillin Resistant Staphylococcus Aureus Infection - An Investigator-initiated, Multi-centre, Parallel Group, Open Labelled Randomised Controlled Trial
CAMERA 2 - Combination Antibiotic Therapy for Methicillin Resistant Staphylococcus Aureus Infection - An Investigator-initiated, Multi-centre, Parallel Group, Open Labelled Randomised Controlled Trial
Enrollment Status: Terminated
Publish Date: December 19, 2018
Intervention Type: Drug
Study Phase: Phase 3
Randomized Controlled Trial of Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Due to Ceftriaxone Non-susceptible E. Coli and Klebsiella Species.
Randomized Controlled Trial of Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Due to Ceftriaxone Non-susceptible E. Coli and Klebsiella Species.
Enrollment Status: Terminated
Publish Date: November 27, 2017
Intervention Type: Drug
Study Phase: Phase 4
View 2 Less Clinical Trials

368 Total Publications

Vertical Vaccination Against Infant Influenza Hospitalization in a Tropical Setting.
Vertical Vaccination Against Infant Influenza Hospitalization in a Tropical Setting.
Journal: JAMA network open
Published: August 11, 2026

Frequently Asked Questions about David C. Lye

Is David C. Lye a top-rated expert for Dengue Fever?

MediFind is an objective health platform that identifies experts based on real-world data. David C. Lye is classified as an Elite expert for Dengue Fever, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does David C. Lye participate in research or clinical trials?

Yes. David C. Lye has published 368 articles and abstracts on conditions like Dengue Fever. You can view a list of David C. Lye's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Lye's expertise for a condition
ConditionClose
View All 22 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile